Introduction: A prospective randomised study involving 810 elderly patients was conducted in an attempt to compare alternating chemotherapy with conventional ®rst-line chemotherapy in aggressive non-Hodgkin's lymphoma in order to improve prognosis with an acceptable toxicity for elderly patients. Patients and methods: Patients included were 55 ± 69 years old and had at least one adverse prognostic factor. Patients were treated either with ACVBP followed by consolidation (n=396) or with an alternating regimen (n=414). This regimen was an association of active drugs in NHL relapsing patients, alternating VIMMM with ACVBP for induction and alternation of VIM and ACVM in consolidation. Eight hundred and sixty-six patients were randomised. After histological review, 810 patients met the inclusion criteria: 396 in arm A, 414 in arm B. Results: The complete response rate after induction was superior for conventional ®rst-line therapy (58.5% vs 48%, P=0.003) but at the end of treatment, the CR rate was not statistically dierent (52% vs 48%, P=0.19). Conventional chemotherapy had a better ®ve-year event-free survival than alternating regimen (33% (95% CI: 30 ± 36%) vs 28% (95% CI: 26 ± 30%), P=0.0289) but overall survival was not statistically dierent (40% (CI 95% 38 ± 42%) vs 36% (CI 95% 34 ± 38%), P=0.068). In this elderly high risk population, the toxicity was very high: 19% in arm A and 26% in arm B died during treatment. Conclusion: Alternating regimen did not improve outcome, was less ecient and more toxic.
Introduction
The treatment of aggressive lymphoma patients has been considerably improved by the use of combination chemotherapy. The CHOP regimen has become the standard regimen, leading to 30 ± 40% long-term survival without dierence in ecacy compared with other regimens. 1 On the other hand, high-dose CHOP regimen (ACVBP regimen) such as developed by the multi-centre French-Belgian Study Group for Adult Lymphoma (Groupe d'Etudes des Lymphomes de l'Adulte GELA) made for 50% long-term survival. 2 However, the outcome in aggressive lymphoma depends on the presence of adverse prognostic factors, as de®ned by the International Non-Hodgkin's Lymphoma Prognostic Factors Project (IPI). 3 Five-year survival varies from 73% for low-risk to 26% for high-risk patients. Therefore suitable strategies must be chosen according to risk factors and more aggressive treatments have to be developed for patients with the poorest outcomes.
Because growth factors were not available in 1987, the population of patients aged 55 ± 70 years did not receive myeloablative therapy and transplantation. Nevertheless, they were able to receive more aggressive treatment than the conventional regimen. One of the options was to introduce an alternating therapy, such as that de®ned by a mathematical model 4 that predicts the occurrence of mutations depending on the type of tumour, and predominantly tumour size. According to this assumption, clones resistant to chemotherapy are present before the beginning of treatment; thus, to overcome clinical resistance, a maximum of dierent drugs must be combined. Alternating non-crossresistant chemotherapy is one possibility for combining drugs and preventing the development of resistant tumour cell clones. 5 A variety of combination regimens such as MACOP-B, ProMACE-MOPP and ProMACE CytaBOM have been developed in accordance with this theory. 6, 7 To test this hypothesis the LNH84 regimen based on ACVBP induction and low-toxicity sequential chemotherapy in consolidation, 8 was compared with a new alternating regimen involving VIMMM and ACVBP (see Treatment section) in induction, followed by VIM alternating with ACM in consolidation. New drugs were chosen because of their ecacy in salvage regimens: ifosfamide, VP16 or VM26, Methyl-GAG, methotrexate and mitoxantrone. 9 ± 11 In this prospective study, we treated patients between 55 and 70 years of age with aggressive lymphoma and at least one adverse prognostic factor de®ned in 1987 (before IPI): poor performance status, high number of extranodal sites, large tumour, bonemarrow (BM) or central nervous system (CNS) involvement, Burkitt or lymphoblastic histology.
The main objective was to improve overall survival. The secondary objectives were to increase the complete response rate and the time to treatment failure in this sub-population with aggressive lymphoma, which includes patients who are unable to receive intensive chemotherapy and autologous stem cell transplantation. 13 performance status 41; more than one extranodal site; tumour burden 510 cm in the largest dimension; BM or CNS involvement; and Burkitt's or lymphoblastic subtypes without BM or CNS involvement. Patients were not included in the study if they had a positive serology to human immunode®ciency virus; a concomitant or previous cancer (except in situ cervical carcinoma or skin epithelioma); congestive heart failure; recent myocardial infarction or conduction abnormalities; uncontrolled diabetes mellitus; or liver/kidney failure not related to the lymphoma. This study protocol was approved by the institutional ethics committee and patients gave written informed consent.
Patients and methods

Eligibility criteria
Staging procedure
The staging procedure included a complete physical examination, routine blood chemistry analyses, thoracic X-ray, and computed tomographic (CT) scans of the thorax and abdomen. All patients had a bonemarrow biopsy. Other staging procedures were performed depending on clinical requirements. The number of extranodal sites and the diameter of the largest tumour mass were determined. Patients were staged according to the Ann Arbor system. 14 Performance status was based on the ECOG Scale (0 ± 4). 13 Serum lactate dehydrogenase (LDH) levels were expressed as a percentage of the maximum normal value. b 2 microglobulin level was expressed in mg/l.
Responses were carefully evaluated for all parameters that had been abnormal before therapy. Responses were evaluated after induction and at the end of the treatment.
Histological and immunophenotypic analysis
Histological review by three independent GELA hematopathologists was performed and used for analysis in 83% of patients. The diagnosis of the local pathologist was used for the remaining 17% of patients. The Ki-1 + anaplastic large-cell subtype was added to the categories of the Working Formulation.
Immunophenotypic studies were performed on deparanised tissue sections, using a panel of antibodies directed against B-(CD20/L26, CDw75/ LN1, MB2) and T-(CD3, CD45Ro/UCHL1) cellassociated antigens.
Treatment
A schema of the study is provided in Figure 1 . The LNH84 protocol used in this trial has already been described. No chemotherapy dose-reduction was allowed and the time between cycles was extended in the case of neutropenia.
Patients did not receive any growth factor except for 116 patients included in a double-blind multi-centre phase III trial of rGCSF (Filgrastim) vs placebo: 57 patients received Filgrastim.
Statistical methods
Randomisation was strati®ed according to participating centres. The randomisation sequence was generated by the GELA Cooperative Studies Programme Coordinating Centre, which issued treatment allocation by telephone after con®rmation of patient eligibility. The primary objective of the study was to detect a 15% dierence in survival between the two treatment arms on the basis of a 30% projected threeyear survival period in the LNH84 arm with an a risk=0.05 and a b risk=0.1. Secondary objectives included assessment of response to induction, eventfree survival and toxicity. Information collected at participating centres was sent to the Coordinating Centre for management and review. All information was checked routinely for outliers and erroneous values.
Complete response (CR) was de®ned as the disappearance of all clinically measurable disease for at least one month and partial response (PR) as a reduction of more than 50% of all measurable disease. Uncertain CR (CRu) was de®ned as PR 475% with no evidence of residual mass activity.
Overall survival (OS) was measured from the date of randomisation to the date of death, a last observation or stopping date. Event-free survival (EFS) was calculated from the date of randomisation for all patients to relapse, disease progression, death, date of last observation, or stopping date. Survival curves were calculated using the Kaplan-Meier method. 16 All analyses were performed on an intention-to-treat basis. The stopping date was set as 30 July 1998. Patient characteristics, frequency of adverse reactions and eect of prognostic factors on CR rate were analysed using w 2 test and logistic regression. Survival rates (EFS and OS) were analysed using the log rank test. The Kaplan Meier plot of time to ®rst event was also produced. 16 The Cox proportional hazard model was used after adjustment to the baseline parameters. 17 Concerning regression and Cox model, the results are presented in terms of the odds-ratio for the co-variates eect, the 95% con®dence limits for the odds-ratio and associated probability values. The nominal signi®cance level for the end-points was set to 0.05 (two-sided test).
Results
A total of 866 patients entered the trial between October 1987 and March 1993. After histological reexamination, patients (n=56) with follicular lymphomas (n=26), small diuse lymphocytic lymphomas Figure 1 Outline of the study. Arm A is the reference arm (ACVBP+consolidation). Arm B is the experimental arm alternating chemotherapy.
The Hematology Journal Alternating chemotherapy in aggressive lymphoma A Bosly et al (n=20), carcinomas (n=4), Burkitt's lymphomas with BM involvement (n=3), Hodgkin's disease (n=3) were excluded. Thus, remaining patients (n=810) met the inclusion criteria and were randomised for treatment with the LNH84 regimen (Arm A; n=395) or with the alternating treatment as described above (Arm B; n=415). Median follow-up time was 80 months.
Characteristics
The mean age of patients in both arms was 62 years (Table 1) . Two patients 555 years were included in Arm A and one patient who was 70 years old was included in Arm B. No statistical dierences were observed in the characteristics of patients in the two treatments groups. Patients had several adverse prognosis factors including age 460 years (63%); tumour size 510 cm (51%); high LDH level (64%); advanced disease stage (80%); poor performance status (38%); two or more extranodal sites (47%); CNS involvement (11%); BM involvement (37%); high b 2 microglobulin level (49%); low serum albumin (24%); and B symptoms (57%). According to the IPI classi®cation, 13% had a low risk (0 ± 1 factor), 25% a low intermediate risk (2 factors), 33% a high intermediate risk (3 factors) and 28% a high risk (4 ± 5 factors).
Response
Response to treatment was assessed in 785 of the 810 patients. For 25 patients, the precise evaluation of response was not available owing to the absence of adequate restaging. At the end of induction in arm A (Figure 1 ), 58.5% of the patients had CR or CRu, 17% had PR, 9% showed failure and 16% died. In arm B, 48% had CR or CRu, 21% had PR, 8% showed failure and 23% died (P=0.049).
Arm A (ACVB) had a better CR rate (58.5%) than arm B (48%) (P=0.003). At the end of treatment in arm A, 52% had CR or CRu, 8% PR, 21% failure and 18% died, in arm B, 48% had CR or CRu, 11% PR, 15% failure and 26% died. The CR rate was 52% for arm A and 48% for arm B (P=0.19). The initial dierence disappeared at the end of the treatment because, in arm B, 15% of the CR progressed and 35% of the PR obtained a CR, as compared with 18 and 29%, respectively, in arm A. Logistic regression analysis of response identi®ed three independent parameters: (1) 
Toxicity
Death during treatment occurred in 18% of cases in arm A and 26% of cases in arm B. Death was due to toxicity, whether or not associated with progression in 70% of cases, to progression of lymphoma only in 8% and to other causes in 22%. Fourteen per cent of the patients who died during treatment were in CR.
Severe neutropenia (4grade 2) occurred in the majority of patients during the ®rst course (89% in arm A, 87% in arm B). The occurrence of severe thrombocytopenia (4grade 2) was comparable in both arms (28%). Severe infection (4grade 2) during induction was 42% in arm A and 49% in arm B. Death from infection during induction was 9% in arm A and 14% in arm B. These toxicities never increased in proportion to the age of the patients, but always in proportion to the IPI score ( Table 2) . (4, 5) 28 28
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Survival
Event-free survival calculated at ®ve years was 30% (95% CI: 28 ± 32) (for arm A: 33% (95% CI: 30 ± 36) and for arm B: 28% (95% CI: 26 ± 30)) (P=0.0289) (Figure 2) . Overall survival at ®ve years was 38% (95% CI: 36 ± 40) (for arm A: 40% (95% CI: 38 ± 42) and for arm B: 36% (95% CI: 34 ± 38)) (P=0.068) (Figure 3 ). Depending on the IPI score (low, low-intermediate, high-intermediate and high risk), the percentages of ®ve-year survival were respectively 52% (47 ± 57), 48% (44 ± 52), 33% (30 ± 36), 26% (23 ± 29) (P50.0001) (Figure 4) . No dierence between the two arms was observed when data were strati®ed according to the IPI score.
In univariate analysis, male-sex; involvement of BM, spleen, liver or CNS; advanced stage; B symptoms; LDH or b 2 elevation; low albumin level; two or more extranodal sites; and poor performance status were associated with poor prognosis. The Cox model identi®ed ECOG 52 (P=0.001); BM involvement (P=0.0078); albumin 530 g/l (P=0.0176) and LDH (P=0.0405) as independent adverse prognosis factors. Arm B (alternating regimen) was a marginally signi®cant (P=0.0624) independent factor for predicting a poor prognosis.
Discussion
The population included in this trial, ineligible for myeloablative chemotherapy in the absence of growth factors, was tested to receive a more intensive chemotherapy than the standard CHOP regimen. The selection of these poor-risk patients was made on the basis of prognostic factors determined prior to initiating treatment at start of study. In accordance with IPI classi®cation, only 13% of this population was at low-risk (0 or 1 factor).
In this population of elderly, poor-risk patients, the toxicity of both arms was high, with 18 and 26% of deaths at the end of consolidation. Respectively, 9 and 14% of patients in Arm A and Arm B died from infection. Non-infectious toxic deaths were due to cardio-respiratory failures or to metabolic disturbances (tumour lysis syndrome). Deaths were related to severe infection and to progression or toxicity in 70% of cases. Most patients died at the time when response was not complete or not assessable. A high level of BM involvement and the high proportion of poor performance status may explain this high level of mortality.
In younger populations, ACVBP plus consolidation is the reference arm for treatment 2 and is associated with a small proportion (4%) of toxic deaths.
The basis of this study was to test the principle of the alternating regimen as previously described. 4, 5 The ®rst attempts to test this hypothesis were the MACOP-B regimen 6 or ProMACE-CytaBOM. 7 However, in a prospective randomised trial, 1 the simple CHOP regimen was shown to have the same ecacy as MACOP-B or ProMACE-CytaBOM.
In our study, for the alternation with ACVBP, we chose drugs active in relapsing patients: ie Ifosfamide, The Hematology Journal Alternating chemotherapy in aggressive lymphoma A Bosly et al VP16 or VM26, mitoxantrone, methyl-GAG and methotrexate (MIME or VIM 9 ± 11 protocols). Other active drugs (platinum and high-dose AraC) were not used because of their known toxicity in elderly patients. 18 Our results in a larger number of patients are comparable to those previously published Phase III studies testing alternating vs conventional regimens. The EORTC study 19 (n=184) compared a CHOP-like regimen (CHVmP-VB) with the alternating ProMACE-MOPP regimen (n=162) reported a higher C rate for CHVmP-VB (61%) than for ProMACE-MOPP (48%) (P50.0005), but survival rates were not dierent. A German study 20 comparing CHOEP (CHOP+ etoposide n=95) with an alternating regimen (hCHOP/IVEP n=90) observed no dierence in CR rate, survival or EFS. A UK study comparing B-CHOP-M (167 patients) with alternation of PEECM and B-CHOP-M (158 patients) showed no dierence in CR rate, or relapse-free and overall survival. 21 We observed, as in the EORTC study, a better CR rate for a non-alternating regimen, and no dierence in terms of survival was observed in either arm. This absence of dierence remains even after strati®cation of risk factors. Thus, no advantage can be demonstrated for an alternating regimen. Moreover, in our study, as in the EORTC study, the alternating regimen was more toxic.
Our results do show that ACVBP plus sequential consolidation was superior to the alternating regimen in terms of EFS. An improved EFS could be related to a higher CR rate at the end of induction. However, CR rate at the end of the treatment was not dierent and this was probably related to there being no dierence in OS.
